Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL629630 | 0.85 | ALDH1A1 (0.39) | MAOBALDH1A1KEAP1NFE2L2BCHE | |
| SCHEMBL3918404 | 0.76 | ALDH1A1 (0.52) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL3917977 | 0.76 | KEAP1 (0.50) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL646518 | 0.76 | ALDH1A1 (0.54) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL630512 | 0.76 | ACHE (0.49) | MAOBBCHEACHEMAOA | |
| SCHEMBL3917277 | 0.75 | ALDH1A1 (0.48) | ALDH1A1KEAP1NFE2L2 | |
| SCHEMBL4956387 | 0.75 | ALDH1A1 (0.53) | ALDH1A1KEAP1NFE2L2MAPK1 | |
| SCHEMBL629617 | 0.75 | MAOB (0.49) | MAOBBCHEACHE | |
| SCHEMBL28576993 | 0.74 | ALDH1A1 (0.44) | ALDH1A1KEAP1NFE2L2MAPK1 | |
| SCHEMBL27737966 | 0.74 | ALDH1A1 (0.47) | ALDH1A1KEAP1NFE2L2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | MAOB 1091/4885ALDH1A1 2690/4885KEAP1 1341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.